Screener
Insmed INSM Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| R&D by Product | ||||||
| ARIKAYCE external R&D expenses | $6.23M-43.4% | $8.62M-28.9% | $9.1M-39.6% | $9.21M-43.7% | $11M-26.1% | |
| Brensocatib external R&D expenses | $13.83M-58.8% | $18.48M-10.5% | $22.94M-4.2% | $19.36M+12.0% | $33.56M-11.2% | |
| Other external R&D expenses | $48.84M+71.7% | $32.68M+16.4% | $36.76M+3.6% | $36.58M+35.9% | $28.45M+90.7% | |
| TPIP external R&D expenses | $38.94M+88.6% | $37.34M+308% | $35.65M+71.8% | $28.75M+72.9% | $20.65M+39.8% | |
| Product revenues, net by Geography | ||||||
| International | $46.75M+20.7% | $35.9M+25.7% | $45.88M+25.2% | $40.31M+51.8% | $38.73M— | |
| US | $378.74M+451% | $270.07M+320% | $217.96M+222% | $102.04M+52.6% | $68.68M+7.7% |
FAQ
- How does Insmed break its business down?
- Insmed (INSM) reports r&d by product across 5 parts — ARIKAYCE external R&D expenses, Brensocatib external R&D expenses, INS1148, Other external R&D expenses and TPIP external R&D expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Insmed's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insmed's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
